5 Key Takeaways
-
1
More than half of glaucoma patients experience chronic ocular surface disease (OSD) due to eyedrop therapy affecting tear film stability.
-
2
Evaluating glaucoma patients for OSD is essential to detect symptoms that may not be reported, impacting their adherence to glaucoma medications.
-
3
Non-drop therapies, such as intracameral implants and selective laser trabeculoplasty, can reduce eyedrop burden and prevent OSD.
-
4
Minimally invasive glaucoma surgery (MIGS) offers a viable treatment option for glaucoma patients, minimizing OSD associated with traditional therapies.
-
5
Effective OSD treatment in glaucoma patients requires initial screening and may include preservative-free medications and advanced therapies like cryopreserved amniotic membrane.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.